Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes

BMC Genomics

Volumn 16, Issue 1, 2015, Pages

  Guo, Yan ^a   Bosompem, Amma ^b   Mohan, Sanjay ^b   Erdogan, Begum ^b   Ye, Fei ^c   Vickers, Kasey C ^b   Sheng, Quanhu ^a   Zhao, Shilin ^a   Li, Chung I ^d   Su, Pei Fang ^e   Jagasia, Madan ^b   Strickland, Stephen A ^b   Griffiths, Elizabeth A ^f   Kim, Annette S ^b,g  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

DNA methyltransferase inhibitor; MicroRNA (miRNA); Myelodysplastic syndromes (MDS); Next generation (deep) sequencing (NGS); Predictive biomarkers; Response to therapy; Transfer RNA (tRNA)

Indexed keywords

AZACITIDINE; DECITABINE; MICRORNA; TRANSFER RNA;

ARTICLE; BONE MARROW BIOPSY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MYELODYSPLASTIC SYNDROME; NEXT GENERATION SEQUENCING; PREDICTIVE VALUE; PREVALENCE; RNA ANALYSIS; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; AGED; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; MALE; MYELODYSPLASTIC SYNDROMES; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES;

AGED; BASE SEQUENCE; FEMALE; GENE EXPRESSION REGULATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MICRORNAS; MYELODYSPLASTIC SYNDROMES; RNA, TRANSFER;

EID: 84960098803     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/s12864-015-1929-y     Document Type: Article

References (108)

1. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57-63.
2. Shendure J. The beginning of the end for microarrays? Nat Methods. 2008;5(7):585-7.
3. Guo Y, Sheng Q, Li J, Ye F, Samuels DC, Shyr Y. Large Scale Comparison of Gene Expression Levels by Microarrays and RNAseq Using TCGA Data. PLoS One. 2013;8(8):e71462.
4. Guo Y, Li CI, Ye F, Shyr Y. Evaluation of read count based RNAseq analysis methods. BMC Genomics. 2013;14 Suppl 8:S2.
5. Asmann YW, Klee EW, Thompson EA, Perez EA, Middha S, Oberg AL, et al. 3' tag digital gene expression profiling of human brain and universal reference RNA using Illumina Genome Analyzer. BMC Genomics. 2009;10:531.
6. Cloonan N, Forrest AR, Kolle G, Gardiner BB, Faulkner GJ, Brown MK, et al. Stem cell transcriptome profiling via massive-scale mRNA sequencing. Nat Methods. 2008;5(7):613-9.
7. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y. RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res. 2008;18(9):1509-17.
8. Martens-Uzunova ES, Olvedy M, Jenster G. Beyond microRNA - Novel RNAs derived from small non-coding RNA and their implication in cancer. Cancer Lett. 2013;340:201-11.
9. Kawaji H, Nakamura M, Takahashi Y, Sandelin A, Katayama S, Fukuda S, et al. Hidden layers of human small RNAs. BMC Genomics. 2008;9(1):157.
10. Cole C, Sobala A, Lu C, Thatcher SR, Bowman A, Brown JW, et al. Filtering of deep sequencing data reveals the existence of abundant Dicer-dependent small RNAs derived from tRNAs. RNA. 2009;15(12):2147-60.
11. Lee YS, Shibata Y, Malhotra A, Dutta A. A novel class of small RNAs: tRNA-derived RNA fragments (tRFs). Genes Dev. 2009;23(22):2639-49.
12. Thompson DM, Parker R. Stressing out over tRNA cleavage. Cell. 2009;138(2):215-9.
13. Guo Y, Bosompem A, Zhong X, Clark T, Shyr Y, Kim AS. A comparison of microRNA sequencing reproducibility and noise reduction using mirVana and TRIzol isolation methods. Int J Comput Biol Drug Des. 2014;7(2-3):102-12.
14. Han L, Vickers KC, Samuels DC, Guo Y. Alternative applications for distinct RNA sequencing strategies. Brief Bioinform. 2014;16:629-39.
15. Vickers KC, Roteta LA, Hucheson-Dilks H, Han L, Guo Y. Mining diverse small RNA species in the deep transcriptome. Trends Biochem Sci. 2015;40(1):4-7.
16. Liao JY, Ma LM, Guo YH, Zhang YC, Zhou H, Shao P, et al. Deep sequencing of human nuclear and cytoplasmic small RNAs reveals an unexpectedly complex subcellular distribution of miRNAs and tRNA 3' trailers. PLoS One. 2010;5(5):e10563.
17. Garcia-Silva MR, Cabrera-Cabrera F, Guida MC, Cayota A. Hints of tRNA-Derived Small RNAs Role in RNA Silencing Mechanisms. Genes (Basel). 2012;3(4):603-14.
18. Fu H, Feng J, Liu Q, Sun F, Tie Y, Zhu J, et al. Stress induces tRNA cleavage by angiogenin in mammalian cells. FEBS Lett. 2009;583(2):437-42.
19. Harada F, Dahlberg JE. Specific cleavage of tRNA by nuclease S1. Nucleic Acids Res. 1975;2(6):865-71.
20. Agris PF. The importance of being modified: an unrealized code to RNA structure and function. RNA. 2015;21(4):552-4.
21. Woodson SA, Muller JG, Burrows CJ, Rokita SE. A primer extension assay for modification of guanine by Ni(II) complexes. Nucleic Acids Res. 1993;21(23):5524-5.
22. Ryvkin P, Leung YY, Silverman IM, Childress M, Valladares O, Dragomir I, et al. HAMR: high-throughput annotation of modified ribonucleotides. Rna-a Publication of the Rna Society. 2013;19(12):1684-92.
23. Jackman JE, Montange RK, Malik HS, Phizicky EM. Identification of the yeast gene encoding the tRNA m1G methyltransferase responsible for modification at position 9. RNA. 2003;9(5):574-85.
24. Alazami AM, Hijazi H, Al-Dosari MS, Shaheen R, Hashem A, Aldahmesh MA, et al. Mutation in ADAT3, encoding adenosine deaminase acting on transfer RNA, causes intellectual disability and strabismus. J Med Genet. 2013;50(7):425-30.
25. Abbasi-Moheb L, Mertel S, Gonsior M, Nouri-Vahid L, Kahrizi K, Cirak S, et al. Mutations in NSUN2 cause autosomal-recessive intellectual disability. Am J Hum Genet. 2012;90(5):847-55.
26. Najmabadi H, Hu H, Garshasbi M, Zemojtel T, Abedini SS, Chen W, et al. Deep sequencing reveals 50 novel genes for recessive cognitive disorders. Nature. 2011;478(7367):57-63.
27. Frye M, Watt FM. The RNA methyltransferase Misu (NSun2) mediates Myc-induced proliferation and is upregulated in tumors. Curr Biol. 2006;16(10):971-81.
28. Berg M, Agesen TH, Thiis-Evensen E, Merok MA, Teixeira MR, Vatn MH, et al. Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci. Mol Cancer. 2010;9:100.
29. Bartlett JM, Thomas J, Ross DT, Seitz RS, Ring BZ, Beck RA, et al. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res. 2010;12(4):R47.
30. Wei FY, Suzuki T, Watanabe S, Kimura S, Kaitsuka T, Fujimura A, et al. Deficit of tRNA(Lys) modification by Cdkal1 causes the development of type 2 diabetes in mice. J Clin Invest. 2011;121(9):3598-608.
31. Kirchhoff K, Machicao F, Haupt A, Schafer SA, Tschritter O, Staiger H, et al. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia. 2008;51(4):597-601.
32. Omori S, Tanaka Y, Takahashi A, Hirose H, Kashiwagi A, Kaku K, et al. Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population. Diabetes. 2008;57(3):791-5.
33. Yasukawa T, Suzuki T, Ueda T, Ohta S, Watanabe K. Modification defect at anticodon wobble nucleotide of mitochondrial tRNAs(Leu) (UUR) with pathogenic mutations of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. J Biol Chem. 2000;275(6):4251-7.
34. Yasukawa T, Kirino Y, Ishii N, Holt IJ, Jacobs HT, Makifuchi T, et al. Wobble modification deficiency in mutant tRNAs in patients with mitochondrial diseases. FEBS Lett. 2005;579(13):2948-52.
35. Kirino Y, Goto Y, Campos Y, Arenas J, Suzuki T. Specific correlation between the wobble modification deficiency in mutant tRNAs and the clinical features of a human mitochondrial disease. Proc Natl Acad Sci U S A. 2005;102(20):7127-32.
36. Gattermann N, Wulfert M, Junge B, Germing U, Haas R, Hofhaus G. Ineffective hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome. Blood. 2004;103(4):1499-502.
37. Erdogan B, Bosompem A, Peng D, Han L, Smith E, Kennedy ME, et al. Methylation of promoters of microRNAs and their host genes in myelodysplastic syndromes. Leukemia & lymphoma. 2013;54:2720-7.
38. Erdogan B, Facey C, Qualtieri J, Tedesco J, Rinker E, Isett RB, et al. Diagnostic microRNAs in myelodysplastic syndrome. Exp Hematol. 2011;39(9):915-26:e912.
39. Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117(26):7121-5.
40. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008;451(7176):335-9.
41. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2010;16(1):49-58.
42. Dostalova Merkerova M, Krejcik Z, Votavova H, Belickova M, Vasikova A, Cermak J. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome. Eur J Hum Genet. 2011;19(3):313-9.
43. Hussein K, Theophile K, Busche G, Schlegelberger B, Gohring G, Kreipe H, et al. Aberrant microRNA expression pattern in myelodysplastic bone marrow cells. Leuk Res. 2010;34(9):1169-74.
44. Pons A, Nomdedeu B, Navarro A, Gaya A, Gel B, Diaz T, et al. Hematopoiesis-related microRNA expression in myelodysplastic syndromes. Leuk Lymphoma. 2009;50:1854-9.
45. Sokol L, Caceres G, Volinia S, Alder H, Nuovo GJ, Liu CG, et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol. 2011;153(1):24-32.
46. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536-42.
47. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
48. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24(24):3895-903.
49. Bejar R, Lord A, Stevenson K, Bar-Natan M, Perez-Ladaga A, Zaneveld J, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705-12.
50. Abaigar M, Ramos F, Benito R, Diez-Campelo M, Sanchez-del-Real J, Hermosin L, et al. Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine. Ann Hematol. 2013;92(11):1543-52.
51. Valencia A, Masala E, Rossi A, Martino A, Sanna A, Buchi F, et al. Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia. 2014;28(3):621-8.
52. Figueroa ME, Skrabanek L, Li Y, Jiemjit A, Fandy TE, Paietta E, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009;114(16):3448-58.
53. Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009;23(6):1019-28.
54. Mund C, Hackanson B, Stresemann C, Lubbert M, Lyko F. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res. 2005;65(16):7086-90.
55. Meldi K, Qin T, Buchi F, Droin N, Sotzen J, Micol JB, et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest. 2015;125(5):1857-72.
56. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-25.
57. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnetjournal. 2011;17:10-2.
58. Guo Y, Zhao S, Sheng Q, Ye F, Li J, Lehmann B, et al. Multi-perspective quality control of Illumina exome sequencing data using QC3. Genomics. 2014;103:323-8.
59. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10(3):R25.
60. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42(Database issue):D68-73.
61. Flicek P, Amode MR, Barrell D, Beal K, Billis K, Brent S, et al. Ensembl 2014. Nucleic Acids Res. 2014;42(Database issue):D749-55.
62. Miller AC, Obholzer ND, Shah AN, Megason SG, Moens CB. RNA-seq-based mapping and candidate identification of mutations from forward genetic screens. Genome Res. 2013;23(4):679-86.
63. Duitama J, Srivastava P, Mandoiu I. Towards accurate detection and genotyping of expressed variants from whole transcriptome sequencing data. BMC Genomics. 2012;13 Suppl 2:S6.
64. Piskol R, Ramaswami G, Li JB. Reliable Identification of Genomic Variants from RNA-Seq Data. Am J Hum Genet. 2013;93(4):641-51.
65. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22(3):568-76.
66. Guo Y, Zhao S, Ye F, Sheng Q, Shyr Y. MultiRankSeq: Multiperspective Approach for RNAseq Differential Expression Analysis and Quality Control. BioMed Res International. 2014;2014:8.
67. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11(10):R106.
68. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139-40.
69. Hardcastle TJ, Kelly KA. baySeq: empirical Bayesian methods for identifying differential expression in sequence count data. BMC Bioinformatics. 2010;11:422.
70. Zou H, Hastie T. Regularization and variable selection via the elastic net (vol B 67, pg 301, 2005). J Royal Stat Soc Series B-Stat Method. 2005;67:768.
71. Tibshirani R. Regression shrinkage and selection via the Lasso. J Royal Stat Soc Series B-Stat Method. 1996;58(1):267-88.
72. Zhao S, Guo Y, Sheng Q, Shyr Y. Advanced Heat Map and Clustering Analysis Using Heatmap3. BioMed Research International. 2014;2014:6.
73. Chen ML, Logan TD, Hochberg ML, Shelat SG, Yu X, Wilding GE, et al. Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction. Blood. 2009;114(19):4045-53.
74. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150(2):264-78.
75. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-87.
76. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-98.
77. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20(12):1472-8.
78. Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science. 1988;242(4882):1171-3.
79. O'Brien TD, Jia P, Xia J, Saxena U, Jin H, Vuong H, et al. Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer. Methods. 2015;83:118-27.
80. Mohr S, Ghanem E, Smith W, Sheeter D, Qin Y, King O, et al. Thermostable group II intron reverse transcriptase fusion proteins and their use in cDNA synthesis and next-generation RNA sequencing. RNA. 2013;19(7):958-70.
81. Enyeart PJ, Mohr G, Ellington AD, Lambowitz AM. Biotechnological applications of mobile group II introns and their reverse transcriptases: gene targeting, RNA-seq, and non-coding RNA analysis. Mob DNA. 2014;5:2.
82. Shen PS, Park J, Qin YD, Li XM, Parsawar K, Larson MH, et al. Rqc2p and 60S ribosomal subunits mediate mRNA-independent elongation of nascent chains. Science. 2015;347(6217):75-8.
83. Katibah GE, Qin YD, Sidote DJ, Yao J, Lambowitz AM, Collins K. Broad and adaptable RNA structure recognition by the human interferon-induced tetratricopeptide repeat protein IFIT5. Proc Natl Acad Sci U S A. 2014;111(33):12025-30.
84. Yamasaki S, Ivanov P, Hu GF, Anderson P. Angiogenin cleaves tRNA and promotes stress-induced translational repression. J Cell Biol. 2009;185(1):35-42.
85. Adams CM, Eischen CM. Inactivation of p53 Is Insufficient to Allow B Cells and B-Cell Lymphomas to Survive Without Dicer. Cancer Res. 2014;74(14):3923-34.
86. Anglesio MS, Wang Y, Yang W, Senz J, Wan A, Heravi-Moussavi A, et al. Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage. J Pathol. 2013;229(3):400-9.
87. Heravi-Moussavi A, Anglesio MS, Cheng SW, Senz J, Yang W, Prentice L, et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med. 2012;366(3):234-42.
88. Zeviani M, Muntoni F, Savarese N, Serra G, Tiranti V, Carrara F, et al. A MERRF/MELAS overlap syndrome associated with a new point mutation in the mitochondrial DNA tRNA(Lys) gene. Eur J Hum Genet. 1993;1(1):80-7.
89. Thorburn DR, Rahman S. Mitochondrial DNA-Associated Leigh Syndrome and NARP. Seattle: University of Washington; 1993.
90. Mahjoub S, Sternberg D, Boussaada R, Filaut S, Gmira F, Mechmech R, et al. A novel mitochondrial DNA tRNAIle (m.4322dupC) mutation associated with idiopathic dilated cardiomyopathy. Diagn Mol Pathol. 2007;16(4):238-42.
91. Bataillard M, Chatzoglou E, Rumbach L, Sternberg D, Tournade A, Laforet P, et al. Atypical MELAS syndrome associated with a new mitochondrial tRNA glutamine point mutation. Neurology. 2001;56(3):405-7.
92. Vissing J, Salamon MB, Arlien-Soborg P, Norby S, Manta P, DiMauro S, et al. A new mitochondrial tRNA(Met) gene mutation in a patient with dystrophic muscle and exercise intolerance. Neurology. 1998;50(6):1875-8.
93. del Mar O'CM, Emperador S, Lopez-Gallardo E, Jou C, Bujan N, Montero R, et al. New mitochondrial DNA mutations in tRNA associated with three severe encephalopamyopathic phenotypes: neonatal, infantile, and childhood onset. Neurogenetics. 2012;13(3):245-50.
94. Tang XW, Li RH, Zheng J, Cai Q, Zhang T, Gong SS, et al. Maternally inherited hearing loss is associated with the novel mitochondrial tRNA(Ser(UCN)) 7505 T > C mutation in a Han Chinese family. Mol Genet Metab. 2010;100(1):57-64.
95. Seibel P, Lauber J, Klopstock T, Marsac C, Kadenbach B, Reichmann H. Chronic Progressive External Ophthalmoplegia Is Associated with a Novel Mutation in the Mitochondrial Trna(Asn) Gene. Biochem Bioph Res Co. 1994;204(2):482-9.
96. Lehtonen MS, Moilanen JS, Majamaa K. Increased variation in mtDNA in patients with familial sensorineural hearing impairment. Hum Genet. 2003;113(3):220-7.
97. Scaglia F, Vogel H, Hawkins EP, Vladutiu GD, Liu LL, Wong LJ. Novel homoplasmic mutation in the mitochondrial tRNATyr gene associated with atypical mitochondrial cytopathy presenting with focal segmental glomerulosclerosis. Am J Med Genet A. 2003;123A(2):172-8.
98. Levinger L, Jacobs O, James M. In vitro 3 '-end endonucleolytic processing defect in a human mitochondrial tRNA(Ser(UCN)) precursor with the U7445C substitution, which causes non-syndromic deafness. Nucleic Acids Res. 2001;29(21):4334-40.
99. Seneca S, Goemans N, Van Coster R, Givron P, Reybrouck T, Sciot R, et al. A mitochondrial tRNA aspartate mutation causing isolated mitochondrial myopathy. Am J Med Genet A. 2005;137(2):170-5.
100. Levinger L, Morl M, Florentz C. Mitochondrial tRNA 3 ' end metabolism and human disease. Nucleic Acids Res. 2004;32(18):5430-41.
101. Merante F, Tein I, Benson L, Robinson BH. Maternally Inherited Hypertrophic Cardiomyopathy Due to a Novel T-to-C Transition at Nucleotide-9997 in the Mitochondrial Trna(Glycine) Gene. Am J Hum Genet. 1994;55(3):437-46.
102. Pancrudo J, Shanske S, Coku J, Lu J, Mardach R, Akman O, et al. Mitochondrial myopathy associated with a novel mutation in mtDNA. Neuromuscul Disord. 2007;17(8):651-4.
103. Elson JL, Swalwell H, Blakely EL, McFarland R, Taylor RW, Turnbull DM. Pathogenic Mitochondrial tRNA Mutations - Which Mutations Are Inherited and Why? Hum Mutat. 2009;30(11):E984-92.
104. Wong LJC, Yim D, Bai RK, Kwon H, Vacek MM, Zane J, et al. A novel mutation in the mitochondrial tRNA (Ser(AGY)) gene associated with mitochondrial myopathy, encephalopathy, and complex I deficiency. J Med Genet. 2006;43(9):e46.
105. Zsurka G, Schroder R, Kornblum C, Rudolph J, Wiesner RJ, Elger CE, et al. Tissue dependent co-segregation of the novel pathogenic G12276A mitochondrial tRNALeu(CUN) mutation with the A185G D-loop polymorphism. J Med Genet. 2004;41(12):e124.
106. Mimaki M, Hatakeyama H, Komaki H, Yokoyama M, Arai H, Kirino Y, et al. Reversible infantile respiratory chain deficiency: a clinical and molecular study. Ann Neurol. 2010;68(6):845-54.
107. Mayr-Wohlfart U, Paulus C, Henneberg A, Rodel G. Mitochondrial DNA mutations in multiple sclerosis patients with severe optic involvement. Acta Neurol Scand. 1996;94(3):167-71.
108. Wong LJC, Liang MH, Kwon H, Bai RK, Alper O, Gropman A. A cystic fibrosis patient with two novel mutations in mitochondrial DNA: Mild disease led to delayed diagnosis of both disorders. Am J Med Genet. 2002;113(1):59-64.